Special Issue

Drug-Drug Interactions

Message from the Guest Editors

Drug-drug interactions (DDIs) cause one drug to affect other drugs, leading to a reduced drug efficacy or an increased toxicity of the affected drugs. Traditionally, DDIs have been evaluated around the selective action of drugs on specific CYP enzymes. The interaction of drugs based on CYPs is very important, but recently, other important mechanisms have also been studied as contributing to the drug interactions, such as drug transporter- or UDP-glucuronyltransferase-mediated DDI. In addition, the novel mechanism to regulate DDI can also be suggested. In the case of the substance to be interacted, not only the DDI, but also the herb- or food-drug interactions have been reported to be clinically relevant in terms of adverse side effects. Reporting examples of drug interactions on a marketed drug or a new mechanism study will be very helpful for preventing the side effects of the patient taking them. This Special Issue has the aim of highlighting the current progress in the clinical or non-clinical interactions of commercial drugs and the elucidation of the mechanism of drug interactions.

Guest Editors

Prof. Dr. Dong Hyun Kim

Department of Pharmacology and PharmacoGenomics Research Center, Inje University College of Medicine, Inje University, Busan 47392, Republic of Korea

Prof. Dr. Sangkyu Lee

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, Republic of Korea

Deadline for manuscript submissions

closed (31 July 2020)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/27208

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

